Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

2484719-15-3Abiraterone Isopropyl Ether

● Under Development

Catalogue No.:	VL830021
CAS No.:	2484719-15-3
Mol. Formula:	C27H37NO
Mol. Weight:	391.6 g/mol

How can we help?

Add to RFQ list

Additional information on CAS 2484719-15-3

Parent drug

Abiraterone

IUPAC Name

3-((3S,8R,9S,10R,13S,14S)-3-Isopropoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridine

Pharmacopoeial Synonyms

N/A

Other Synonyms

3-[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-3-propan-2-yloxy-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl]pyridine; 3.BETA.-ISOPROPOXY-17-(PYRIDIN-3-YL)ANDROSTA-5,16-DIENE; PYRIDINE, 3-(3-(1-METHYLETHOXY)ANDROSTA-5,16-DIEN-17-YL)-; Pyridine, 3-[3- (1- methylethoxy)androsta-5,16-dien-17-yl]-;

Smiles

C[C@@]12C(C3=CC=CN=C3)=CC[C@@]1([H])[C@]4([H])CC=C5C[C@@H](OC(C)C)CC[C@]5(C)[C@@]4([H])CC2

InChI

InChI=1S/C27H37NO/c1-18(2)29-21-11-13-26(3)20(16-21)7-8-22-24-10-9-23(19-6-5-15-28-17-19)27(24,4)14-12-25(22)26/h5-7,9,15,17-18,21-22,24-25H,8,10-14,16H2,1-4H3/t21-,22-,24-,25-,26-,27+/m0/s1

Description

Abiraterone Isopropyl Ether is a meticulously characterized reference material that complies with rigorous regulatory requirements, including those defined by USP, EMA, JP, and BP. This product plays a crucial role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Abiraterone. It is further supported by a detailed Structure Elucidation Report (SER), ensuring high accuracy and reliability across a broad range of analytical applications. Abiraterone Isopropyl Ether (CAS No: 2484719-15-3) might be present as an impurity of Abiraterone is a poorly water-soluble drug used in the treatment of prostate cancer that is discharged in the form of a prodrug of an acetate possessing slightly higher solubility than abiraterone in biorelevant media.

References

Gala, Urvi H., et al. â€œThe Effect of Drug Loading on the Properties of Abirateroneâ€“Hydroxypropyl Beta Cyclodextrin Solid Dispersions Processed by Solvent Free KinetiSolÂ® Technology.â€Â European Journal of Pharmaceutics and Biopharmaceutics, vol. 165, Aug. 2021, pp. 52â€“65, https://doi.org/10.1016/j.ejpb.2021.05.001.